CLINICAL_TRIALS
trial_result
· 2016-01-01
Clinical Trial Update: Study Evaluating ACC-001 in Japanese Patients With Mild To Moderate Alzheimer's Disease [Phase 2]
Summary
Pfizer announced results from a Phase 2 trial of ACC-001 in Japanese patients with mild to moderate Alzheimer's disease.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Pfizer | Conditions: Alzheimer Disease | Phase 2 | Status: COMPLETED | Results posted: 2016-01-01